A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings

Patients with relapsed or refractory multiple myeloma have undergone two or three previous therapies are now being treated with a humanized IgG1 monoclonal antibody elotuzumab (HuLuc63) that targets F7 signalling lymphocytic activation molecule F7 (SLAMF7)- a signalling lymphocytic activation molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghous, Ghulam, Shoukat, Hafiz Muhammad Hassan, Tarar, Zahid Ijaz, Zafar, Muhammad Usman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686952/
https://www.ncbi.nlm.nih.gov/pubmed/33251069
http://dx.doi.org/10.7759/cureus.11162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686952/
https://www.ncbi.nlm.nih.gov/pubmed/33251069
http://dx.doi.org/10.7759/cureus.11162

Ejemplares similares